CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.54 Million SEK | -79.24% |
| 2022 | 26.69 Million SEK | -68.23% |
| 2021 | 84.04 Million SEK | 676.18% |
| 2020 | 10.82 Million SEK | -27.75% |
| 2019 | 14.98 Million SEK | 183867.85% |
| 2018 | 8146.00 SEK | -99.73% |
| 2017 | 3 Million SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | -100.0% |
| 2024 Q1 | 326 Thousand SEK | -45.3% |
| 2023 Q1 | 2.16 Million SEK | 113.61% |
| 2023 Q4 | 596 Thousand SEK | -48.84% |
| 2023 Q3 | 1.16 Million SEK | -34.84% |
| 2023 FY | 5.54 Million SEK | -79.24% |
| 2023 Q2 | 1.78 Million SEK | -17.53% |
| 2022 Q3 | 13.52 Million SEK | 185.48% |
| 2022 FY | 26.69 Million SEK | -68.23% |
| 2022 Q1 | 11.4 Million SEK | -86.43% |
| 2022 Q2 | 4.73 Million SEK | -58.45% |
| 2022 Q4 | -15.93 Million SEK | -217.81% |
| 2021 Q2 | 839 Thousand SEK | -83.61% |
| 2021 Q1 | 5.11 Million SEK | 164.41% |
| 2021 Q3 | 423 Thousand SEK | -49.58% |
| 2021 Q4 | 84.04 Million SEK | 19767.98% |
| 2021 FY | 84.04 Million SEK | 676.18% |
| 2020 Q3 | 2.67 Million SEK | 23.69% |
| 2020 Q2 | 2.16 Million SEK | -46.75% |
| 2020 Q1 | 4.05 Million SEK | 28.25% |
| 2020 FY | 10.82 Million SEK | -27.75% |
| 2020 Q4 | 1.93 Million SEK | -27.59% |
| 2019 Q3 | 7.05 Million SEK | 124.74% |
| 2019 Q4 | 3.16 Million SEK | -55.12% |
| 2019 FY | 14.98 Million SEK | 183867.85% |
| 2019 Q1 | 1.63 Million SEK | 1119763.01% |
| 2019 Q2 | 3.13 Million SEK | 91.87% |
| 2018 Q1 | 50 Thousand SEK | 0.0% |
| 2018 FY | 8146.00 SEK | -99.73% |
| 2018 Q4 | 146.00 SEK | -98.18% |
| 2018 Q3 | 8000.00 SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2017 Q1 | 3 Million SEK | 0.0% |
| 2017 FY | 3 Million SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 Q3 | 450 Thousand SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 90.459% |
| Ziccum AB (publ) | 3.74 Million SEK | -47.961% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.1% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 89.018% |
| Mendus AB (publ) | 28.48 Million SEK | 80.538% |
| Genovis AB (publ.) | 158.23 Million SEK | 96.496% |
| Intervacc AB (publ) | 8.01 Million SEK | 30.828% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -26.752% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 96.747% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 87.37% |
| Aptahem AB (publ) | 2.63 Million SEK | -110.751% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -435.663% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -7100.152% |
| Fluicell AB (publ) | 3.33 Million SEK | -66.091% |
| Saniona AB (publ) | 16.84 Million SEK | 67.078% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 66.209% |
| Biovica International AB (publ) | 7.29 Million SEK | 23.949% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -360.858% |
| AcouSort AB (publ) | 10.55 Million SEK | 47.454% |
| Xintela AB (publ) | 78 Thousand SEK | -7007.842% |
| Abliva AB (publ) | 137 Thousand SEK | -3946.801% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 90.375% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -175.279% |
| OncoZenge AB (publ) | 3000.00 SEK | -184703.9% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -3476.85% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.541% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.677% |
| Corline Biomedical AB | 25.03 Million SEK | 77.85% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 2.358% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -668.948% |
| I-Tech AB | 120.86 Million SEK | 95.413% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 95.865% |
| Cyxone AB (publ) | 5.14 Million SEK | -7.695% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 21.36% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 48.014% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 50.631% |
| Nanologica AB (publ) | 1.44 Million SEK | -284.208% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -10360.598% |
| BioInvent International AB (publ) | 71.46 Million SEK | 92.242% |
| Alzinova AB (publ) | 270 Thousand SEK | -1953.377% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 84.259% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -278.95% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -96.461% |
| Simris Alg AB (publ) | 4.35 Million SEK | -27.334% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -4164.705% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 97.678% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -24004.857% |